Skip to main content
SpringerLink
Log in

Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model

  • Original Paper
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

Epidemiological studies indicate that a higher plasma level of uric acid (UA) associates with the reduced risk of Parkinson’s disease (PD). To confirm the role of UA as a biomarker for PD, we evaluated changes in the serum UA level in the 6-hydroxydopamine (6-OHDA)-induced hemiparkinsonism in rat. For this purpose, 6-OHDA was administered in the medial forebrain bundle by stereotaxic surgery. According to the apomorphine-induced rotational test, the increased intensity of behavioral symptoms as a function of time was associated with the further reduction of UA level. On the other hand, the level of UA increased in the midbrain of the injured hemisphere. The level of reduction in the serum UA level of rats with severe and moderate symptoms was significantly higher than that of rats with mild symptoms. The immunohistofluorescence and biochemical analyses showed that the serum UA level was also correlated with the death of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra pars compacta (SNc), reduced level of striatal dopamine, and severity of oxidative stress in the midbrain. The rats with mild symptoms also showed a significant decrease in TH-positive neurons and striatal dopamine level. These findings suggest a positive correlation between the level of reduction in the serum urate level and severity of 6-OHDA-induced Parkinsonism. In addition, our findings indicated that UA had no marked neuroprotective effects, at least at concentrations obtained in this study. On the other hand, UA was introduced as a biomarker for PD, as a significant decline was observed in the serum UA level of rats with mild behavioral symptoms but with significant dopaminergic cell death in the SNc.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373(9680):2055–2066. https://doi.org/10.1016/S0140-6736(09)60492-X

    Article  CAS  PubMed  Google Scholar 

  2. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5):384–386

    Article  CAS  PubMed  Google Scholar 

  3. Moon HE, Paek SH (2015) Mitochondrial dysfunction in Parkinson’s disease. Exp Neurobiol 24:103–116. https://doi.org/10.5607/en.2015.24.2.103

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tsang AHK, Chung KKK (2009) Oxidative and nitrosative stress in Parkinson’s disease. Biochem Biophys Acta 1792:643–650. https://doi.org/10.1016/j.bbadis.2008.12.006

    CAS  PubMed  Google Scholar 

  5. Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39(6):889–909. https://doi.org/10.1016/S0896-6273(03)00568-3

    Article  CAS  PubMed  Google Scholar 

  6. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson’s disease. Neurol 47:S161–S170

    Article  CAS  Google Scholar 

  7. Shulman JM, De Jager PL, Feany MB (2011) Parkinson’s disease: genetics and pathogenesis. Annu Rev Pathol 6:193–222. https://doi.org/10.1146/annurev-pathol-011110-130242

    Article  CAS  PubMed  Google Scholar 

  8. Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376. https://doi.org/10.1136/jnnp.2007.131045

    Article  CAS  PubMed  Google Scholar 

  9. Frasier M, Chowdhury S, Eberling J, Sherer T (2010) Biomarkers in Parkinson’s disease: a funder’s perspective. Biomark Med 4(5):723–729. https://doi.org/10.2217/bmm.10.89

    Article  CAS  PubMed  Google Scholar 

  10. Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78(11):6858–6862

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yeum KJ, Russell RM, Krinsky NI, Aldini G (2004) Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys 430(1):97–103. https://doi.org/10.1016/j.abb.2004.03.006

    Article  CAS  PubMed  Google Scholar 

  12. Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull 33(4):419–425

    Article  CAS  PubMed  Google Scholar 

  13. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM (1996) Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol 144(5):480–484

    Article  CAS  PubMed  Google Scholar 

  14. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58(5):797–800. https://doi.org/10.1002/ana.20663

    Article  PubMed  Google Scholar 

  15. Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A (2007) Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 166(5):561–567. https://doi.org/10.1093/aje/kwm127

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Alonso A, Rodríguez LA, Logroscino G, Hernán MA (2007) Gout and risk of Parkinson disease: a prospective study. Neurology 69(17):1696–1700. https://doi.org/10.1212/01.wnl.0000279518.10072.df

    Article  PubMed  Google Scholar 

  17. Chen H, Mosley TH, Alonso A, Huang X (2009) Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 169(9):1064–1069. https://doi.org/10.1093/aje/kwp033

    Article  PubMed  PubMed Central  Google Scholar 

  18. Schwarzschild MA, Macklin EA, Ascherio A (2014) Parkinson Study Group SURE-PD Investigators: urate and neuroprotection trials. Lancet Neurol 13(8):758. https://doi.org/10.1016/S1474-4422(14)70138-3

    Article  PubMed  Google Scholar 

  19. De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H (2008) Gout and the risk of Parkinson’s disease: a cohort study. Arthritis Rheum 59(11):1549–1554. https://doi.org/10.1002/art.24193

    Article  PubMed  Google Scholar 

  20. Annanmaki T, Muuronen A, Murros K (2007) Low plasma uric acid level in Parkinson’s disease. Mov Disord 15(8):1133–1137

    Article  Google Scholar 

  21. Vieru E, Köksal A, Mutluay B, Dirican AC, Altunkaynak Y, Baybas S (2016) The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson’s disease. Neurol Sci 37(5):743–747. https://doi.org/10.1007/s10072-015-2471-z

    Article  PubMed  Google Scholar 

  22. Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, Tsoutsou A, Zournas C, Zissimopoulos V, Vassilopoulos D (2009) Serum uric acid levels in patients with Parkinson’s disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 111(9):724–728. https://doi.org/10.1016/j.clineuro.2009.06.012

    Article  PubMed  Google Scholar 

  23. Bové J, Perier C (2012) Neurotoxin-based models of Parkinson’s disease. Neuroscience 211:51–76. https://doi.org/10.1016/j.neuroscience.2011.10.057

    Article  PubMed  Google Scholar 

  24. Blandini F, Armentero MT, Martignoni E (2008) The 6-ydroxydopamine model: news from the past. Parkinsonism Relat Disord 14(Suppl 2):S124–S129. https://doi.org/10.1016/j.parkreldis.2008.04.015

    Article  PubMed  Google Scholar 

  25. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, 6th edn. Academic Press, San Diego

    Google Scholar 

  26. Fujita M, Nishino H, Kumazaki M, Shimada S, Tohyama M, Nishimura T (1996) Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Mol Brain Res 39:127–136

    Article  CAS  PubMed  Google Scholar 

  27. Sarookhani MR, Haghdoost-Yazdi H, Sarbazi-Golezari A, Babayan-Tazehkand A, Rastgoo N (2017) Involvement of adenosine triphosphate -sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine- induced animal model of Parkinson’s disease. Behav Pharmacol. https://doi.org/10.1097/FBP.0000000000000358

    Google Scholar 

  28. Sarukhani M, Haghdoost-Yazdi H, Sarbazi A, Babayan-Tazehkand A, Dargahi T, Rastgoo N (2018) Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine- induced animal model of Parkinson’s disease: behavioral, histological and biochemical studies. Neurol Res (unpublished data)

  29. Zhang N, Shu HY, Huang T, Zhang QL, Li D, Zhang GQ, Peng XY, Liu CF, Luo WF, Hu LF (2014) Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLoS ONE 9(6):e100286. https://doi.org/10.1371/journal.pone.0100286

    Article  PubMed  PubMed Central  Google Scholar 

  30. Zhu TG, Wang XX, Luo WF, Zhang QL, Huang TT, Xu XS, Liu CF (2012) Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci Lett 506(2):175–179. https://doi.org/10.1016/j.neulet.2011.10.075

    Article  CAS  PubMed  Google Scholar 

  31. Gong L, Zhang QL, Zhang N, Hua WY, Huang YX, Di PW, Huang T, Xu XS, Liu CF, Hu LF, Luo WF (2012) Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson’s disease: linking to Akt/GSK3β signaling pathway. J Neurochem 123(5):876–885. https://doi.org/10.1111/jnc.12038

    Article  CAS  PubMed  Google Scholar 

  32. De Luca MA, Cauli O, Morelli M, Simola N (2014) Elevation of striatal urate in experimental models of Parkinson’s disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration? J Neurochem 131(3):284–289. https://doi.org/10.1111/jnc.12809

    Article  PubMed  Google Scholar 

  33. Fitzmaurice PS, Ang L, Guttman M, Rajput AH, Furukawa Y, Kish SJ (2003) Nigral glutathione deficiency is not specific for idiopathic Parkinson’s disease. Mov Disord 18(9):969–976. https://doi.org/10.1002/mds.10486

    Article  PubMed  Google Scholar 

  34. Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF (2010) Uric acid as a CNS antioxidant. J Alzheimers Dis 19(4):1331–1336. https://doi.org/10.3233/JAD-2010-1330

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, Snyder J, Zhu YG, Ling ZD (2005) 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci 22(5):1158–1168. https://doi.org/10.1111/j.1460-9568.2005.04281.x

    Article  CAS  PubMed  Google Scholar 

  36. Cooper PH, Novin D, Butcher LL (1982) Intracerebral 6-hydroxydopamine produces extensive damage to the blood-brain barrier in rats. Neurosci Lett 30(1):13–18

    Article  CAS  PubMed  Google Scholar 

  37. Paganoni S, Schwarzschild MA (2017) Urate as a marker of risk and progression of neurodegenerative disease. Neurotherapeutics 14(1):148–153. https://doi.org/10.1007/s13311-016-0497-4

    Article  CAS  PubMed  Google Scholar 

  38. Wen M, Zhou B, Chen YH, Ma ZL, Gou Y, Zhang CL, Yu WF, Jiao L (2017) Serum uric acid levels in patients with Parkinson’s disease: a meta-analysis. PLoS ONE 12(3):e0173731. https://doi.org/10.1371/journal.pone.0173731

    Article  PubMed  PubMed Central  Google Scholar 

  39. Yuan H, Sarre S, Ebinge G, Michotte Y (2005) Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson’s disease. J Neurosci Methods 144:35–45. https://doi.org/10.1016/j.jneumeth.2004.10.004

    Article  PubMed  Google Scholar 

  40. Abrous DN, Rodriguez JJ, Montaron MF, Aurousseau C, Le Moal M, Barneoud P (1998). Behavioural recovery after unilateral lesion of the dopaminergic mesotelencephalic pathway: effect of repeated testing. Neurosci 84:213–221

    Article  CAS  Google Scholar 

  41. Iancu R, Mohapel P, Brundin P, Paul G (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice. Behav Brain Res 162:1–10. https://doi.org/10.1016/j.bbr.2005.02.023

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Mrs. Ayda Faraji for her assistance in stereotaxic surgeries and Ms. Zare for her contribution to immunohistofluorescence experiments. This study was supported by a Grant-in-aid for scientific research from the Research Council of Qazvin University of Medical Sciences.

Author information

Authors and Affiliations

  1. Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, 3414951414, Iran

    Mohammad Reza Sarukhani & Hashem Haghdoost-Yazdi

  2. Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran

    Gilda Khandan-Chelarci

Authors
  1. Mohammad Reza Sarukhani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hashem Haghdoost-Yazdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gilda Khandan-Chelarci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hashem Haghdoost-Yazdi.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sarukhani, M.R., Haghdoost-Yazdi, H. & Khandan-Chelarci, G. Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model. Neurochem Res 43, 1086–1095 (2018). https://doi.org/10.1007/s11064-018-2522-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-018-2522-y

Keywords

Search

Navigation